Alvaro Teijeira

List of Publications by Year
in descending order

66 papers	4,066 citations	147801 31 h-index	161849 54 g-index
66 all docs	66 docs citations	66 times ranked	6968 citing authors

#	Article	IF	Citations
1	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. Immunity, 2020, 52, 856-871.e8.	14.3	387
2	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature, 2019, 569, 428-432.	27.8	313
3	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clinical Cancer Research, 2016, 22, 3924-3936.	7.0	306
4	Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treatment Reviews, 2017, 60, 24-31.	7.7	262
5	Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Annals of Oncology, 2017, 28, xii44-xii55.	1.2	170
6	The HIF-1Î± Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy. Cancer Discovery, 2012, 2, 608-623.	9.4	156
7	Intralymphatic CCL21 Promotes Tissue Egress of Dendritic Cells through Afferent Lymphatic Vessels. Cell Reports, 2016, 14, 1723-1734.	6.4	143
8	Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes. Cancer Research, 2011, 71, 801-811.	0.9	137
9	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
10	T Cell Trafficking through Lymphatic Vessels. Frontiers in Immunology, 2016, 7, 613.	4.8	121
11	IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy. Clinical Cancer Research, 2021, 27, 2383-2393.	7.0	108
12	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. Cancer Cell, 2019, 36, 613-629.e7.	16.8	99
13	IL-1 Coordinates the Neutrophil Response to C. albicans in the Oral Mucosa. PLoS Pathogens, 2016, 12, e1005882.	4.7	98
14	T Cell Migration from Inflamed Skin to Draining Lymph Nodes Requires Intralymphatic Crawling Supported by ICAM-1/LFA-1 Interactions. Cell Reports, 2017, 18, 857-865.	6.4	96
15	Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7551-7556.	7.1	92
16	Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116.		91
17	New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open, 2019, 4, e000733.	4.5	80
18	Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation. Cancer Immunology Research, 2018, 6, 798-811.	3.4	62

#	Article	IF	Citations
19	Cellular cytotoxicity is a form of immunogenic cell death. , 2020, 8, e000325.		61
20	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virusâ€"Derived Vectors Fosters Dendritic Cellâ€"Mediated T-cell Cross-Priming. Cancer Research, 2018, 78, 6643-6654.	0.9	60
21	T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63â€"Polyubiquitin-Dependent Signals from Endosomes. Journal of Immunology, 2013, 190, 6694-6706.	0.8	56
22	Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium. International Journal of Radiation Oncology Biology Physics, 2017, 97, 389-400.	0.8	55
23	Taking the lymphatic route: dendritic cell migration to draining lymph nodes. Seminars in Immunopathology, 2014, 36, 261-274.	6.1	54
24	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Letters, 2022, 529, 70-84.	7.2	51
25	Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFNâ€Î±. European Journal of Immunology, 2010, 40, 3054-3063.	2.9	49
26	Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on <scp>IL</scp>â€8. Journal of Pathology, 2021, 255, 190-201.	4.5	49
27	Lymphatic Endothelium Forms Integrin-Engaging 3D Structures during DC Transit across Inflamed Lymphatic Vessels. Journal of Investigative Dermatology, 2013, 133, 2276-2285.	0.7	48
28	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Antiâ€"PD-1 and Anti-CD137 Monoclonal Antibodies. Journal of Thoracic Oncology, 2016, 11, 524-536.	1.1	48
29	Metabolic Consequences of T-cell Costimulation in Anticancer Immunity. Cancer Immunology Research, 2019, 7, 1564-1569.	3.4	48
30	CD137 on inflamed lymphatic endothelial cells enhances CCL21â€guided migration of dendritic cells. FASEB Journal, 2012, 26, 3380-3392.	0.5	45
31	A Transgenic Prox1-Cre-tdTomato Reporter Mouse for Lymphatic Vessel Research. PLoS ONE, 2015, 10, e0122976.	2.5	41
32	Intratumoral injection of interferonâ€Î± and systemic delivery of agonist antiâ€CD137 monoclonal antibodies synergize for immunotherapy. International Journal of Cancer, 2011, 128, 105-118.	5.1	39
33	Repetitive Nicotine Exposure Leads to a More Malignant and Metastasis-Prone Phenotype of SCLC: A Molecular Insight into the Importance of Quitting Smoking during Treatment. Toxicological Sciences, 2010, 116, 467-476.	3.1	36
34	Novel strategies exploiting interleukin-12 in cancer immunotherapy. , 2022, 239, 108189.		35
35	Initial Afferent Lymphatic Vessels Controlling Outbound Leukocyte Traffic from Skin to Lymph Nodes. Frontiers in Immunology, 2013, 4, 433.	4.8	33
36	Phosphorylated tubulin adaptor protein CRMPâ€2 as prognostic marker and candidate therapeutic target for NSCLC. International Journal of Cancer, 2013, 132, 1986-1995.	5.1	32

#	Article	IF	Citations
37	Differential Interleukinâ€8 thresholds for chemotaxis and netosis in human neutrophils. European Journal of Immunology, 2021, 51, 2274-2280.	2.9	32
38	ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes. Frontiers in Immunology, 2018, 9, 2084.	4.8	31
39	Repurposing the yellow fever vaccine for intratumoral immunotherapy. EMBO Molecular Medicine, 2020, 12, e10375.	6.9	28
40	CD69 is a direct HIF-1Î± target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes. OncoImmunology, 2017, 6, e1283468.	4.6	27
41	Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death. Theranostics, 2020, 10, 4481-4489.	10.0	24
42	Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	24
43	Dendritic Cells and T Cells Interact Within Murine Afferent Lymphatic Capillaries. Frontiers in Immunology, 2019, 10, 520.	4.8	23
44	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. , 2021, 9, e002953.		23
45	Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. Cancer Discovery, 2022, 12, 1356-1377.	9.4	22
46	CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nature Communications, 2021, 12, 7296.	12.8	22
47	Cellular immunotherapies for cancer. OncoImmunology, 2017, 6, e1306619.	4.6	17
48	A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFÎ±, and IL-1Î². Cancer Discovery, 2022, 12, 2140-2157.	9.4	16
49	Microinjection for the <i>ex Vivo</i> Modification of Cells with Artificial Organelles. ACS Nano, 2017, 11, 7758-7769.	14.6	15
50	Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications. Cancers, 2021, 13, 963.	3.7	12
51	Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms. Cellular and Molecular Immunology, 2020, 17, 576-586.	10.5	12
52	Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. , 2022, 10, e003532.		8
53	Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4â€“1BB). OncoImmunology, 2018, 7, e1368605.	4.6	7
54	Cancer Immunosurveillance Caught in the Act. Immunity, 2016, 44, 525-526.	14.3	6

#	Article	IF	Citations
55	Cancer immunotherapy full speed ahead. Annals of Oncology, 2017, 28, xii1-xii2.	1.2	6
56	Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy. Cancer Discovery, 2018, 8, 794-796.	9.4	6
57	Editorial: Breaching their way through: Neutrophils destroy intercellular junctions to transmigrate rapidly across lymphatic endothelium. Journal of Leukocyte Biology, 2015, 98, 880-882.	3.3	5
58	Firefighters for the Wrong Type of Inflammation in Tumors. Cancer Discovery, 2021, 11, 2372-2374.	9.4	3
59	Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis. OncoImmunology, 2022, 11, .	4.6	3
60	Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing. Clinical Cancer Research, 2016, 22, 4277-4279.	7.0	2
61	Abstract 3538: The HIF-1Î± hypoxia response in mouse tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. , 2012, , .		1
62	Abstract 639: Morphological changes in mitochondria induced by CD137 (4-1BB) co-stimulation on CD8 T cells. , 2017, , .		1
63	Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer. , 2018, , 429-446.		0
64	Abstract 4740: Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment ofactivated T lymphocytes. , 2011, , .		0
65	Abstract B2: T cell costimulation in cancer immunotherapy with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.. , 2013, , .		0
66	Abstract 4015: Exposure of lymphatic endothelial cells to ionizing radiation increases the surface expression levels of integrin ligands. , 2016, , .		0